|
Adilipoline™ (CL413)
Adilipoline™ (S-(2,3-bis(palmitoyloxy)- (2RS)propyl)- (R)-cysteinyl-(S)-seryl-(S)- lysyl- (S)-lysyl- (S)-lysyl- (S)-lysyl 4 -((6-amino-2- (butylamino)-8- hydroxy-9H- purin-9-yl) methyl) aniline) was generated by conjugation of an 8-hydroxyadenine moiety to the terminal acid function of Pam2CSK4.
Adilipoline™ is a good ligand for both TLR2 and TLR7. In vivo tumor studies have demonstrated that Adilipoline™ is a potent antitumor agent. Intratumoral injection of Adilipoline™ in established B16 tumors resulted in tumor regression. However, in contrast to AdiFectin™ (CL347), no protection after tumor rechallenge was observed.
Specificity: TLR2 and TLR7 agonist
Synonym: S-(2,3-bis (palmitoyloxy)-(2RS) propyl)- (R)-cysteinyl- (S)-seryl- (S)-lysyl- (S)-lysyl- (S)-lysyl-(S)- lysyl 4-((6-amino-2- (butylamino)-8-hydroxy- 9H-purin-9-yl)methyl) aniline
Working concentration: 50 pg- 10 µg/ml (~30pM - 10 µM)
Solubility: H2O (1 mg/ml)
Formula: C81H145N17O12S
Molecular weight: 1581 g/mol
Endotoxin level: <0.001 EU/µg
|